SIRNA-BASED COMPOSITION FOR INHIBITING Gal-9 (LGALS9), PREPARATION BASED THEREON AND METHOD OF USING IT AS TARGETED IMMUNOSTIMULANT IN ANTI-PD-L1 THERAPY Russian patent published in 2025 - IPC A61K31/7115 C12N15/113 A61K47/24 A61K47/26 A61P35/00 

FIELD: pharmaceutics; medicine.

SUBSTANCE: group of inventions relates to pharmaceutics and medicine. Object 1 is a composition for enhancing the T-cell immune response by blocking the function of the LGALS9 gene in kidney cancer cells, comprising an agent for delivering short interfering RNAs (siRNA) to target cells, which is liposomes 1,26-bis(cholest-5-en-3β-yloxycarbonylamino)-7,11,16-2-tetraazagexacosane tetrahydrochloride (2X3):1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) in molar ratio of 1:2, and duplex to the LGALS9 gene, formed by two oligonucleotides and containing nucleotide sequences of short interfering RNA. Object 2 – corresponding preparation based on said compositioncharacterized by the fact that it contains a duplex to the LGALS9 gene, cationic liposomes 2X3:DOPE in molar ratio of 1:2, sodium chloride and polysorbate 80. Object 3 – use of the composition for enhancing the T-cell immune response in avelumab therapy.

EFFECT: enhancing the T-cell immune response as a result of increasing the number of effective T-cells capable of initiating the destruction of tumour cells, as well as delivering nucleic acids into the cells and suppressing the LGALS9 gene expressed in tumour cells both in mono-mode and in the treatment with avelumab.

6 cl, 8 dwg, 2 tbl, 4 ex